Thursday, April 27, 2017 5:55:53 PM
the studies include: the ability of 5T4 CAR-T cells to kill
a wide range of 5T4-expressing tumour cell lines in vitro;
the ability of T cells taken from patients with ovarian
cancer to be re-programmed with the 5T4 CAR construct
and respond functionally to their own tumour cells
in vitro through the secretion of cytokines; and the ability
of 5T4 CAR-T cells to control tumour cell growth in
in vivo models. Further data will be presented in due
course either at a conference or in a publication.
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM